162. Pemphigoid Clinical trials / Disease details


Clinical trials : 83 Drugs : 128 - (DrugBank : 51) / Drug target genes : 33 - Drug target pathways : 142

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-005987-67-DE
(EUCTR)
22/12/202116/07/2021A study to see if 24-weeks of treatment with nomacopan works and is safe in adult patients with bullous pemphigoid who are also being treated with steroid tabletsA randomized, part A partial blinded and part B double blinded, placebo-controlled 24-week clinical study to evaluate the efficacy and safety of nomacopan therapy in adult patients with bullous pemphigoid receiving adjunct oral corticosteroid therapy (ARREST-BP) moderate to severe bullous pemphigoid
MedDRA version: 21.1;Level: LLT;Classification code 10006567;Term: Bullous pemphigoid;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: nomacopan
Product Code: rVA576
INN or Proposed INN: NOMACOPAN
Other descriptive name: rVA576
Akari Therapeutics PlcNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
48Phase 3United States;Germany
2NCT05061771
(ClinicalTrials.gov)
September 202115/9/2021Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)A Randomized, Part A Partial Blinded and Part B Double Blinded, Placebo-controlled 24-week Clinical Study to Evaluate the Efficacy and Safety of Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)Bullous PemphigoidDrug: nomacopan (rVA576);Other: PlaceboAKARI TherapeuticsNULLNot yet recruiting18 Years99 YearsAll148Phase 3NULL